Vikram Limaye, managing director and chief executive officer of the National Stock Exchange of India, on Wednesday said derivatives were not the “weapons of mass destruction” they were made out to be. At least not in India.

This perception was based on how the derivatives  are structured globally, where most of the transactions are ‘over the counter’. “Equity derivatives contracts in India can be traded only on recognised stock exchanges. The Securities and Exchange Bo­ard of India (Sebi) has put together a well thought-out framework for trading that mandates use of advanced statistical and risk management tools including margining and position limits. The regulator has also kept out complicated and exotic products that are provided in international markets,” Limaye said at an event commemorating 25 years of the benchmark Nifty50 index and 20 years of the exchange’s derivatives segment.

Sebi Chairman Ajay Tyagi said increased investor participation in domestic  is an extremely encouraging sign for the growth of capital .

Tyagi said India had seen a significant increase in individual  accessing the capital markets. The cumulative demat accounts, which stood at 36 million in March 2019, rose to 77 million as of the end of November 2021.

“So, in fact, what was achieved in over two decades in the market has been achieved in the last about two-and-a-half years,” said Tyagi.

 on their part need to make informed  decisions based on their risk appetite, especially in the case of derivatives.

It is critical to apprise  how these products can be used to hedge their risks so that they do not get their fingers burned and disappointed from the capital market,” Tyagi said.

The Sebi chairman said the equity cash markets will move from T+2 to T+1 settlements in a phased manner from next month and this will reduce uncertain exposures.

Union Commerce minister Piyush Goyal, the chief guest at the function, said stock exchanges must establish a strong system to maintain transparency to encourage the common man to invest in stocks.

The daily average turnover for single stock derivatives increased 5.4 times to Rs 89,487 crore during the same period. The same stocks in the underlying cash market saw an increase of 5.5 times in daily average turnover to Rs 51,775 crore.

Nifty50 has delivered annualised returns of 15.2 per cent in the last 10 years and 16.8 per cent in the last 20 years (total index returns as on December 28, 2021). The introduction of the index acted as a precursor to the introduction of equity index derivatives introduced on June 12, 2000. This was followed by the introduction of index options, stock options and stock futures the next year.

Nifty50 now has a virtual monopoly in the index derivatives segment, accounting for over 95 per cent of the total value.

“Nifty has come a long way to evolve as a flagship equity index. Today, the Nifty50 represents 66 per cent of the float adjusted market capitalisation and is seen as a reliable barometer of the Indian equity market,” said Dinesh Kumar Khara, chairman, State Bank of India.

“The index represents almost 80 per cent of the Indian market cap and most of the money managers like ourself as well as international ones look at Nifty50 as a benchmark while measuring the performance of their own schemes,” added A Balasubramanian, MD and CEO, Aditya Birla Sun Life AMC.

“The exchange has made a lot of innovations and value-add in the kind of products they have developed over the years. It is not easy to manage such large derivatives volumes and trades, especially from a risk management and compliance standpoint, and the exchange has done remarkably well in this area,” said Siddarth Bhamre, director — alternative investments and research, InCred Capital.

Limaye, for his part, says the need of the hour is to broad-base investor participation in equity derivatives, especially from insurance companies and banks.

Leave a comment

Vijay Gomatam

Consultant – Investment Banking

Vijay Gomatam has over 20 years of banking experience across M&A, corporate finance, capital markets, and corporate banking, with a strong focus on cross-border deal origination and execution across India, Southeast Asia, Japan, and Australia. He has deep sector expertise in industrials, IT services, media, and telecom, with extensive experience in India - Southeast Asia and India–Japan transactions. Vijay previously served as Director at MUFG Bank, Singapore, where he led the India - Japan M&A corridor, and earlier worked with Deutsche Bank, Merrill Lynch, Houlihan Lokey, and Edelweiss Alternative Asset Advisors.

His transaction experience includes Motherson Group’s acquisition of TSE-listed Yachiyo Industries, Takahata India’s stake sale to SPRL, Toppan Form’s acquisition of PT RDS in Indonesia, Mitsui’s investment in FKS Food & Agri, CVC’s investment in PT LinkNet, and capital market transactions for Southeast Asian media and telecom clients including SingTel, Axiata, and Bakrie Group.

He holds an MBA from IIM Calcutta and a B.E. (Hons.) from Nanyang Technological University, Singapore.

Akbar Khan

Senior Advisor – Investment Banking

Akbar Khan has over twenty years of experience across M&A advisory, Private Equity, and Corporate M&A, along with a decade as an entrepreneur and operator. He has held senior roles at Bank of America Merrill Lynch in India and London, where he led Telecom & Technology Investment Banking, Private Equity coverage, and M&A, and at General Electric, where he served as Head of Corporate Development and M&A for India and the MENA region. He has advised global corporates and financial sponsors including Reuters Plc, Telecom Italia, Hellenic Telecom, MTN, Tata Group, Apax Partners, Warburg Pincus, and TA Associates, and has led several notable transactions. These include advising E2E Networks on

its USD 50M capital raise, QuEST Global on its USD 75M Series B private placement to Warburg Pincus, Rain Technologies on its USD 65M Series A financing from QED Investors and Invus, Augnito.ai on its Pre-Series A raise from Apollo Hospitals Group, Tata Consultancy Services on the acquisition of Citigroup’s captive back-office unit, Forthnet in Greece on the acquisition of Netmed, and Telecom Italia on the sale of Cosmote via a leveraged buyout by Apax Partners and TPG.

In addition, Akbar co-founded and served as CEO of Rain Technologies India an earned wage access fintech platform.

He holds an MBA from London Business School and is a UK-qualified Chartered Accountant.

Shreyan ML

Managing Director – Healthcare & Pharma

Shreyan ML leads the healthcare and pharma investment banking practice and brings over 15 years of experience across investment banking, corporate M&A, and management consulting within the pharmaceutical sector. Prior to joining MAPE, he worked with Spark Capital, Strides Group, Wanbury Limited, and Tata Strategic Management Group.

His deal experience includes advising Curatio Healthcare on the sale of its business to Torrent Pharmaceuticals; Sale of TTK’s human pharma business to Bharat Serums; Glenmark Pharmaceuticals on the sale of the Razel brand to KKR-backed JB Chemicals & Pharma and the sale of nine dermatology brands to Eris Oaknet.

As Corporate M&A Head at Strides Group, he was involved in thesale of Agila to Mylan and led the animal health strategy at Sequent Scientific, executing over 12 transactions including fundraises and cross-border acquisitions.

He holds an MBA from IIM Indore and is a computer engineer from NIT Karnataka.

Arjun Mukherjee

Managing Director – Investment Banking

Arjun Mukherjee brings over 20 years of investment banking experience, with a strong focus on mergers & acquisitions and capital raising across Industrials, Education, Telecom, Cement, and Healthcare sectors. Prior to joining InCred Capital, he was part of the senior leadership team at MAPE Advisory Group for over a decade and has previously worked with Lazard, Ambit Capital, and Macquarie Capital.

His deal experience includes advising Veranda Learning on multiple acquisitions and its IPO, Emami on its bid for Paras Pharma, HeidelbergCement on the acquisitions of Mysore Cement and Indo Rama Cement, Italcementi on the acquisition of Sri Vishnu Cement along with an open offer, Bharti Airtel on the acquisitions of Hexacom India and the Spice Calcutta circle, as well as the sale of NLD rights to VSNL, Advent on its bid for Lafarge India.

He has also advised Jagdale Industries on the sale of its electrolyte drinks brand to Johnson & Johnson, promoters of Orissa Sponge on stake sales to Bhushan Steel and Monnet Ispat and on takeover defence, Fortis Healthcare on takeover defence and the sale of a minority stake to Khazanah, ICI India on the sale of its Nitrocellulose business to Actis and its rubber chemicals business, Jai Balaji Industries on the sale of its DI pipe unit and on QIP fund raising, Orbit Corporation and Ansal APIL on QIP-led equity fund raises, Walton Street Capital on raising a USD 500 million India-focused real estate fund, and on acquisition debt funding for the purchase of the RL Fine Chem API business.

Ashish Ambwani

Managing Director – Investment Banking

Ashish Ambwani has two decades of investment banking experience with a focus on cross-border M&A and Private Equity, and deep sector expertise across Consumption &Retail, Industrials and Digital businesses. He previously served as Director at Lazard for over 12 years and began his career at KPMG.

He has worked on numerous transactions including Osam Dairy’s sale to Dodla Dairy, Livpure’s capital raise from M&G Investments, QIMA’s acquisition of EFRAC Limited, Raymond Consumer Care’s FMCG sale to Godrej Consumer, IPO of Ethos Limited, Manohar Packaging’s sale to Parksons Packaging, MM Polytech’s sale to Huhtamaki, YY Inc.’s acquisition of Bigo, Kama Ayurveda’s fund raise and sale to Puig, Magnet360’s sale to Mindtree, Danone’s acquisition of Wockhardt nutrition assets, UCB’s sale of Indian brands to Dr Reddy’s, Sabero Organics’ sale to Coromandel, International Paper on its acquisition of AP Paper, Avantor on its acquisition of RFCL.

He holds an MBA from IIM Lucknow and a has a degree in Electrical & Electronics Engineering from NIT Trichy.

Jacob Mathew

Consultant- Investment Banking

Jacob Mathew brings over 25 years of experience in investment banking, private equity, and fundraising. He co-founded MAPE Advisory, a boutique investment bank focused on mid-market companies. Prior to MAPE, he was a Vice President (M&A) at Merrill Lynch India and played a key role in setting up the corporate finance practice at PwC India.

He has worked and led numerous transactions including the acquisition of Coats Viyella’s garment business by the AV Birla Group, the sale of Burnol and Coldarin brands, Dr Reddy’s buyout of American Remedies, and the sale of Diamond Dychem to Ciba AG. At MAPE, he led transactions across technology, telecommunications, consumer, healthcare, and retail sectors. His key clients include Coffee Day Enterprises, Strides, Igarashi Motors, J&J India, and Jyothi Labs.

He holds a PGDM from IIM Calcutta and is a Civil Engineer.

M Ramprasad

Consultant – Investment Banking

M Ramprasad has over 25 years of experience across investment banking, private equity, and fundraising. He co-founded MAPE Advisory, a boutique Indian investment bank focused on mid-market companies, which later merged with the Investment banking team at InCred in 2020. Prior to MAPE, he was a Senior Vice President at Merrill Lynch India, leading South India operations.

He has led marquee transactions for leading business groups including Tata Group, DuPont, ICICI Bank, Dr Reddy’s, and Sify, and at MAPE advised on landmark deals across manufacturing, infrastructure, and financial services. His key clients include Murugappa Group, ELGi Equipments, Curatio, Jyothi Labs, Karvy Financial Group, Star Health, and CRH Group.

He holds a PGDM from BIM Trichy and a degree in Chemistry.

Sanjay Singh

Head of Investment Banking – InCred Capital

Sanjay Singh is the Head of Investment Banking at InCred Capital, where he leads coverage across both advisory and equity capital markets. He brings over 20 years of experience across investment banking, strategy, and operations, with deep expertise in the pharmaceuticals and healthcare sectors.

Prior to joining InCred, he held leadership roles at BDA Partners as Head of India and Co-Head of Healthcare Asia, and at KPMG as Partner and Head of Life Sciences in India. He has also worked with Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals.

His transaction experience includes advising Chemfield Cellulose on its divestment to Oji Holdings, Archimica S.p.A. on its acquisition by PI Industries, Synokem Pharmaceuticals on growth investment from TA Associates, Isagro SpA on the divestment of Isagro Asia Agrochemicals to PI Industries, SMT on its equity raise from Morgan Stanley Private Equity, Astec LifeSciences on the sale of equity to Godrej Agrovet and Nihon Nohyaku on its acquisition of Hyderabad Chemical Limited amongst others.

Sanjay holds an MBA from IIM Bangalore and a B Tech from IIT BHU.